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The present study investigated the effects of hot water extracts of 22 medicinal plants used
traditionally to treat diabetes on Dipeptidyl peptidase-IV (DPP-IV) activity both in vitro and
in vivo in high-fat fed (HFF) obese-diabetic rats. Fluorometric assay was employed to de-
termine the DPP-IV activity. For in vivo studies, HFF obese-diabetic rats were fasted for 6
h and blood was sampled at different times before and after the oral administration of the
glucose alone (18 mmol/kg body weight) or with either of the four most active plant extracts
(250 mg/5 ml/kg, body weight) or established DPP-IV inhibitors (10 μmol/5 ml/kg). DPP-IV
inhibitors: sitagliptin, vildagliptin and diprotin A, decreased enzyme activity by a maximum
of 95–99% (P<0.001). Among the 22 natural anti-diabetic plants tested, Anogeissus Lati-
folia exhibited the most significant (P<0.001) inhibitory activity (96 +− 1%) with IC50 and IC25
values of 754 and 590 μg/ml. Maximum inhibitory effects of other extracts: Aegle marmelos,
Mangifera indica, Chloropsis cochinchinensis, Trigonella foenum-graecum and Azadirachta
indica were (44 +−7%; 38 +− 4%; 31+−1%; 28+−2%; 27+−2%, respectively). A maximum of 45%
inhibition was observed with >25 μM concentrations of selected phytochemicals (rutin). A.
latifolia, A. marmelos, T. foenum-graecum and M. indica extracts improved glucose toler-
ance, insulin release, reduced DPP-IV activity and increased circulating active GLP-1 in
HFF obese-diabetic rats (P<0.05–0.001). These results suggest that ingestion of selected
natural anti-diabetic plants, in particular A. latifolia, A. marmelos, T. foenum-graecum and M.
indica can substantially inhibit DPP-IV and improve glucose homeostasis, thereby providing
a useful therapeutic approach for the treatment of T2DM.
Introduction
Diabetes Mellitus has become a worldwide concern, manifesting as one of the most major health issues
within the world’s population. There are several forms of diabetes, including gestational diabetes, but Type
1 and Type 2 diabetes are by far the most prevalent. Type 2 diabetes (T2DM), most often associated with
obesity, is a particularly widespread disease and many patients from all over the globe are afflicted by this
condition. T2DM patients are characterized by impaired β-cell function and insulin secretion together
with tissue insulin resistance [1]. Since the prevalence and associated complications of T2DM are so dam-
aging, more effective therapies are being sought to either delay or prevent the progression of T2DM [2]. As
so, plants are most reliable source as studies to date found that they contain series of potential phytogroups
including alkaloids, glycosides, terpenoids, phenolic, flavonoids and plant-derived peptides, each of them
has shown potential antidiabetic activity in different experiment [2]. Besides, the diet of patients with
T2DM plays a vital role in helping to maintain blood glucose control involving such factors as energy
density, carbohydrate content, dietary fiber and natural products that may directly or indirectly affect the
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Table 1 Traditional use of selected medicinal plants treatment for diabetes
Plants Traditional Uses References
Acacia catechu (L.f.) Willd. Diabetes, obesity, asthma, bronchitis, anaemia, diarrhoea [34,35]
Bunium persicum (Boiss.) B.Fedtsch. Obesity, gastrointestinal and urinary disorders, diarrhoea, asthma [36]
Eugenia jambolana Lam. Diabetes, cancer, enteric disorders, renal problems [37,38]
Linum usitatissimum L. Gastrointestinal disorders, asthma, bronchitis, pulmonary tuberculosis, gingival
disorders, atherosclerosis
[39,40]
Santalum album L. Inflammation, anti-septic, fever, carminative, diuretic, hypotensive, memory booster [41]
Selaginella bryopteris (L.) Jaundice, chronic tracheitis, lung cancer, venereal diseases, colitis, diuretic
problems
[42,43]
Sesamum indicum (White) Dietary fibre, joint inflammation, toothache, scrapes, cuts [44,45]
Tamarindus indica Inflammation, rheumatism, diarrhoea, dysentery, respiration conditions, malaria,
gonorrhoea
[46]
Terminalia arjuna (Roxb. ex DC.) Diabetes, cirrhosis, anaemia, cardiovascular disorders, viral diseases [47,48]
Azadirachta indica Diabetes, urinary and gastrointestinal problems, skin diseases, blood pressure and
cholesterol
[49]
Anogeissus latifolia (Roxb. ex DC.) Diabetes, haemorrhages, diarrhoea, dysentery, skin diseases, leprosy, hepatopathy [50]
Albizia lebbeck (L.) Benth. Respiratory disease, skin diseases, inflammation, diarrhoea, edema [51,52]
Cudrania cochinchinensis (Lour.) Gonorrhoea, rheumatism, jaundice, hepatitis, boils, scabies, bruising [53]
Cassia fistula L. Diabetes, jaundice, piles, rheumatism ulcers, skin eruptions, eczema, heart
diseases, asthma, liver disorder
[54,55]
Dalbergia sissoo DC. Bronchitis, inflammations, gonorrhoea, digestive disorders, colorectal cancer,
bacterial infections
[56]
Swertia chirayita (Roxb.) Diabetes, hypertension, liver disorders, malaria, hepatitis, inflammation, digestive
diseases, epilepsy
[57,58]
Withania coagulans (Stocks) Chronic degenerative diseases, diabetes [59]
Glycyrrhiza glabra L. Dyspepsia, belching, gas stomach ache, intestinal and liver colics, ulcerated
wounds and gastritis
[60]
Momordica charantia L. Diabetes, hypertension, obesity, cancer, hyperlipidaemia, digestive disorders,
microbial infections
[61,62]
Mangifera indica L. Diabetes, hypertension, anaemia, haemorrhage, asthma, gastric disorders [63,64]
Aegle marmelos (L.) Corrêa Diabetes, inflammations, asthma, ophthalmia, diarrhoea, dysentery, cardiac
ailments
[65]
Trigonella foenum-graecum L. Diabetes, hypercholesterolemia, edema lung congestion sinus, indigestion,
baldness
[66,67]
absorption of nutrients or the secretion and action of insulin [3]. Hormones released by the gut in response to nutrient
absorption, most notably GIP and GLP-1, also play an important role in modulating post-prandial hyperglycemia [4].
These hormones have a very short circulating half-life due to inactivation by the enzyme DPP-IV that cleaves the first
two amino acids from the N-terminals producing GIP (3-42) and GLP-1 (9-36) [5]. This is why DPP-IV inhibitors
are beneficial in the treatment of T2DM. Anti-diabetic drugs like metformin and nateglinide that respectively target
insulin action and insulin secretion can, at high concentrations, also suppress DPP IV enzyme activity and such action
may partly explain use of nateglinide as prandial insulin releasing agent that augments GLP-1 levels [6].
Having adequate bioactive insulin in the circulation is the key to control of glucose homeostasis as the hormone
is unique in stimulating tissue glucose uptake and limiting hepatic glucose output. DPP-IV interferes with normal
insulin action by degrading and therefore diminishing the insulinotropic and other β-cell actions of GLP-1 and GIP
[4]. Natural resources are being explored to find new dietary ways to promote healthy blood glucose control including
manipulation of the microbiome [7]. Over the years, many studies have revealed the anti-diabetic activity of plants
used traditionally for the treatment of diabetes and defined their actions mediated via effects on the gastrointestinal
processing of food and both the secretion and action of insulin [8–10]. More recently, dietary components including
dairy, tuna, rice, salmon and amaranth have been found to exhibit DPP-IV inhibitory properties in vitro [11,12].
In the present work, 22 traditional medicinal plants with proven anti-diabetic activity were selected to assess their
effects on DPP-IV enzyme activity in vitro (Tables 1 and 2). Furthermore, four of the most effective plants (A. latifolia,
A. marmelos, T. foenum-graecum and M. indica) were selected to assess their acute effects on plasma DPP-IV
activity, glucose-lowering and insulin-releasing properties in high fat fed obese-diabetic rats.
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Table 2 Antidiabetic actions of selected traditional plants treatment for diabetes
Plants 1Hyperglycemia 2Insulin secretion
3Glucose uptake and
metabolism References
Acacia catechu ↓ ↑ ND [68]
Bunium persicum ↓ ND ↑ [69]
Eugenia jambolana ↓ ↑ ↑ [70]
Linum usitatissimum ↓ ↑ ↑ [71,72]
Santalum album ↓ ↑ ↑ [73]
Selaginella bryopteris ↓ ↑ ↑ [74]
Sesamum indicum (White) ↓ ND ↑ [75]
Tamarindus indica ↓ ↑ ND [76]
Terminalia arjuna ↓ ↑ ↑ [77,78]
Azadirachta indica ↓ ↑ ↑ [79,80]
Anogeissus latifolia ↓ ↑ ND [81]
Albizia lebbeck ↓ ↑ ↑ [82,83]
Chloropsis cochinchinensis ↓ ↑ ↑ [84]
Cassia fistula ↓ ↑ ↑ [85,86]
Dalbergia sisso ↓ ND ND [87,88]
Swertia chirrayita ↓ ↑ ↑ [89]
Withania coagulans ↓ ND ND [90,91]
Licorice glyceriza ↓ ↓ ND [16,92,93]
Momardica chirantia ↓ ↑ ND [94,95]
Mangifera indica ↓ ↑ ↑ [96,97]
Aegle marmelos ↓ ↑ ↑ [21]
Trigonella foenum graecum ↓ ↑ ND [22,98]
Effects of plant: - ↑, increase; ↓, decrease (beneficial effect on hyperglycemia); ND, effect not determined
1Effects on hyperglycemia were demonstrated in mice or rats given streptozotocin or alloxan or high fat diet to induce diabetes.
2Effects on insulin secretion were demonstrated in vitro using pancreatic β-cells or in vivo using blood plasma of rats or mice. Beneficial actions in vitro
were dose-dependent and did not affect cellular viability at low concentrations.
3Effects on glucose uptake and metabolism were demonstrated in vitro using isolated mouse abdominal muscle.
Materials and methods
Plant materials and preparation of extract
Twenty-two plants used traditionally to treat diabetes were purchased to assess their ability to inhibit DPP-IV enzyme
activity and improve glycemic control. The plants selected and their traditional and pharmacological actions are given
in Tables 1 and 2. All plant materials were sourced in India where they are the native species. Confirmation of identity
for the plants was made by a taxonomist Prof. F. A. Khan, Head of Department of Botany, Benazir Govt. Science &
Commerce College, Bhopal, Barkatullah University, Madhya Pradesh, India where the plant specimens have been
deposited in the herbarium. The accession numbers (voucher specimen numbers) for 22 traditional medicinal plants
are listed in Table 3.
All plant components (Tables 1-3) were dried and grounded to obtain a fine powder. About 1 g of each dried powder
was infused using 40 ml of boiled water. Aqueous extracts were chosen based on traditional use and prior studies of
plants selected. The infusion was left for 15 min before being filtered through Whatman no. 1 filter paper. After that,
the filtrates were dried under a vacuum (Savant Speedvac; New York, U.S.A.) to produce plant extract that was used
to perform DPP-IV inhibitory experiments. For this purpose, the dried extract was dissolved in a 100 mM Tris-HCl
buffer at an initial concentration of 5 mg/ml.
Determination of DPP-IV inhibitory activity in vitro
A fluorometric method was used to determine the DPP-IV inhibitory activity of plant extracts based on that described
previously [6,13]. For in vitro studies, a 100 mM Tris-HCl buffer was prepared and adjusted to pH 8.0 using 100 mM
Tris-base. Reactions were performed in 96-well black-walled, clear-bottomed microplates (Premier Scientific Ltd,
Belfast, U.K.) using 8 mU/ml of DPP-IV enzyme and 200 μM of fluorescent substrate (Gly-Pro-AMC) with or with-
out plant extract, known DPP-IV inhibitor or selected phytochemicals. These included caffeine, catechin, epicatechin,
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Table 3 List of confirmation of identity of 22 traditional medicinal plants with their herbarium numbers
Plants Collected parts of plants Voucher specimen numbers
Acacia catechu (L.f.) Willd. Bark 1721
Bunium persicum (Boiss.) B.Fedtsch. Seed 1844
Eugenia jambolana Lam. Seed 1681
Linum usitatissimum L. Seed 1531
Santalum album L. Bark 1168
Selaginella bryopteris (L.) Leaf 1135
Sesamum indicum (White) Seed 1219
Tamarindus indica Seed 866
Terminalia arjuna (Roxb. ex DC.) Bark 535
Azadirachta indica Seed 1610
Anogeissus latifolia (Roxb. ex DC.) Bark 1734
Albizia lebbeck (L.) Benth. Bark 1761
Cudrania cochinchinensis (Lour.) Bark 1241
Cassia fistula L. Stalk 1321
Dalbergia sissoo DC. Bark 335
Swertia chirayita (Roxb.) Bark 581
Withania coagulans (Stocks) Fruit 1196
Glycyrrhiza glabra L. Root 2212
Momordica charantia L. Seed 2378
Mangifera indica L. Seed 2391
Aegle marmelos (L.) Corrêa Leaf 1733
Trigonella foenum-graecum L. Seed 681
gallic acid, isoquercitrin, quercetin and rutin as well as the small molecule anti-diabetic drug nateglinide. DPP-IV as-
say was based on liberation of AMC (7-amino-4-methyl-coumarin) from DPP-IV substrate, Gly-Pro-AMC. Changes
in fluorescence due to cleavage of the molecule by DPP-IV were measured with an excitation and emission at 370
and 440 nm with 2.5 nm slit width using a FlexStation 3 (Molecular Devices, California, U.S.A.). The inhibition of
DPP-IV activity was calculated as the percentage of inhibition by each plant extract at various concentrations. Nei-
ther the plant extracts nor plasma samples showed any loss of activity when stored for many months at 20◦C. It was
checked in control experiments that the extracts did not themselves cleave the substrate or interfere with fluorescence
measurements at the concentrations employed.
Animals
Forty male Sprague-Dawley rats (Envigo, Huntingdon, U.K., approximately 380–400 g) were fed a high-fat diet (45%
fat, 20% protein and 35% carbohydrate; 26.15 kJ/g total energy percent; Special Diet Service, Essex, U.K.), ad libi-
tum for 5–6 weeks to induce obesity and glucose intolerance. An additional 10 age-matched rats were maintained
on standard rodent diet (30% protein, 10% fat, and 60% carbohydrate; 12.99 kJ/g total energy percent; Trouw Nutri-
tion, Cheshire, U.K.). High fat fed rats exhibited increased body weight (398.7 +− 1.6 g versus 384.7 +− 1.8 g; P<0.01),
impaired oral glucose tolerance and enhanced glucose-induced insulin responses, indicative of insulin resistance
compared with the lean control rats fed normal diet (Figure 3). These animals also exhibited significantly elevated
HbA1c levels (5.90 +− 0.07% versus 4.57 +− 0.05%; P<0.001), measured by the point-of-care A1CNow+ kit (PTS Di-
agnostic, Indiana), indicative of mild diabetes. The animals were housed individually in an air-conditioned room
at 22 +− 2◦C with a 12-h light/dark cycle. All animal experiments were conducted in accordance with U.K. Animals
(Scientific Procedures) Act 1986 and EU Directive 2010/63EU. All necessary steps were taken to prevent any poten-
tial animal suffering. The animal studies were approved by local Ulster Animal Welfare and Ethical Review Body
(AWERB) committee (01/10/2016), as well as being covered under a U.K. Home Office Animal project/personal li-
cence numbers PIL450, PIL1822 and PPL 2804, approved on 06/05/2016. All animals were maintained under specific
pathogen-free conditions and experiments were conducted in the Biomedical and Behavioral Research Unit (BBRU)
at Ulster University, Coleraine, U.K. Blood was collected from the cut tip of the tail of conscious animals without need
for anaesthesia. No animals were culled.
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Determination of the acute effects of plant extracts on DPP-IV activity in
vivo
High fat-fed rats were used to study DPP-IV inhibitory activity of four medicinal plants (A. latifolia, A. marmelos T.
foenum-graecum and M. indica) in vivo. Sitagliptin and vidagliptin were used in comparison as positive controls.
Animals were fasted for approximately 6 h prior to experimentation. Blood samples were collected from the cut tip
of the tail from conscious rats before and after oral administration of glucose with or without plant extract (250 mg/5
ml/kg) or an established DPP-IV inhibitor (10 μmol/5 ml/kg) at 0, 30, 60, 120, 180, 240, 360 and 480 min. Samples
were collected in chilled fluoride/heparin-coated micro centrifuge tubes followed by centrifugation at 12000 rpm for 5
min. Plasma was stored at −20◦C for measurement of insulin, DPP-IV activity and active GLP-1 (7-36). An Ascencia
Contour glucose meter (Bayer, Newbury, U.K.) was used to measure blood glucose and insulin was determined by
dextran-charcoal radioimmunoassay [14]. Active GLP-1 (7-36) was determined in the plasma samples collected at 60
min using a specific GLP-1 (Active) ELISA Kit (EGLP-35K, Merck Millipore, Dorset, U.K.).
Statistical analysis
Statistical analysis tests were performed by using Graph Pad-Prism 5. The results are represented as mean +− SEM.
Data were analyzed using by unpaired Student’s t test (nonparametric, with two-tailed P values) and one-way ANOVA
with repeated measures was used and adjusted using Bonferroni correction. P value of < 0.05 was considered signif-
icant.
Results
In vitro DPP-IV Inhibitory effects of plant extracts
The extracts from 22 different plants were evaluated in vitro to assess their effects on DPP-IV activity. Established
DPP-IV inhibitors namely sitagliptin, vildagliptin and diprotin A were used as positive controls (Table 4 and Figure
1A–C). These inhibitors decreased DPP-IV enzyme activity by up to 99 +− 2.0%, 99 +− 3% and 95 +− 3%, with IC50
values of 2.04 × 10−2, 1.70 × 10−2 and 2.39 × 10−3 μg/ml (P<0.05–0.001, respectively (Table 4 and Figure 1A–C).
In the presence of A. latifolia (bark), enzymatic AMC liberation from Gly-Pro-AMC was inhibited by 20 +− 1% to
96 +− 1% (P<0.05–0.001, Table 4, Figure 1D) at concentrations of 200–5000 μg/ml when compared with control.
Moreover, A. marmelos (leaves), M. indica (seeds) and T. foenum-graecum (seeds) significantly inhibited DPP-IV
enzyme activity at concentrations ranging from 200 to 5000 μg/ml (P<0.05–0.001, respectively, Table 4 and Figure
1E–G. The highest inhibitory effects of plant extracts were observed at 5000 μg/ml (44 +− 7%, 38 +− 4%, 31 +− 1%
and 28 +− 2%, P<0.001, respectively, Table 4) as compared with control. The other plant extracts were found to in-
hibit DPP-IV activity in between 9 +− 1% and 27 +− 2% (P<0.05–0.001, Table 4) when tested at a concentration of
5000 μg/ml. The phytochemicals responsible for the inhibitory action are unknown but several possible candidates
known to be present in the plant collection were tested. These included caffeine, catechin, epicatechin, gallic acid, iso-
quercitrin, quercetin and rutin. As shown in Figure 2A–G, each inhibited DPP-IV with the majority exhibiting lower
effective concentrations of 125–200 μM. Isoquercitrin and quercetin inhibited at 25–50 μM whereas rutin was par-
ticularly effective with maximal inhibition of 45% and IC25 value of 306 μM. The effect was similar to the established
insulinotropic drug nateglinide (Figure 2H).
Acute effects of plants extract on glucose tolerance and plasma insulin
in high fat-fed rats
Four plants (A. latifolia, A. marmelos, T. foenum-graecum and M. indica), the most potent in inhibiting in vitro
DPP IV enzyme activity, were selected for evaluation of effects on DPP IV activity and oral glucose tolerance in
high-fat fed rats. Hot water extracts (250 mg/5 ml/kg) substantially improved the glycemic excursion from 30 to
240 min and increased plasma insulin from 30 to 120 min as compared with oral administration of glucose alone
(P<0.05–0.001; Figure 3A,C). Established DPP-IV inhibitors (sitagliptin and vildagliptin) also improved glucose tol-
erance and insulin release following oral administration (P<0.05–0.001; Figure 3B,D).
Acute effects of plant extracts on circulating DPP-IV activity and active
GLP-1 (7-36) in high fat-fed rats
Sitagliptin and vildagliptin significantly reduced DPP-IV activity in high-fat fed rats (P<0.001, Figure 4A–D). Hot
water extracts (250 mg/5 ml/kg) of A. latifolia, A. marmelos, T. foenum-graecum and M. indica also significantly
decreased in vivo DPP-IV enzyme activity compared with glucose alone (P<0.05–0.01, Figure 4A–D). The effects of
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Figure 1. DPP-IV inhibitory activity of (A) Sitagliptin, (B) Vidagliptin, (C) Diprotin-A and hot water extract of four most potent
plants (D) A. latifolia, (E) A. marmelos, (F) T. foenum graecum and (G) M. indica expressed as the bar chart (A–G)
Values are mean +− SEM with n=4, *P<0.05, **P< 0.01 and ***P< 0.001, compared with control. Sitagliptin: 1–10,000 nM; Vidagliptin:
1.6–5000 nM and Diprotin A: 2.5–40 nM.
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Figure 2. DPP-IV inhibitory activity of phytochemicals: (A) caffeine, (B) catechin, (C) epicatechin, (D) gallic acid, (E) iso-
quercitrin, (F) quercetin, (G) rutin and (H) the antidiabetic small molecule drug, nateglinide
Values are mean +− SEM with n=4, *P<0.05, **P<0.01 and ***P< 0.001, compared with control.
A. latifolia and T. foenum-graecum were particularly prominent with a sustained inhibition of DPP-IV activity from
30 min onwards (P<0.05–0.01, Figure 4A,C). Lesser but still significant effects were observed with A. marmelos and
M. indica extracts (P<0.05, Figure 4B,D). As shown in Figure 5, active GLP-1 (7-36) concentrations in plasma were
significantly increased by 32–45% (P<0.05–0.01) at 60 min after administration of each plant extract. An 81–89%
increase was observed with sitagliptin and vidagliptin (P<0.001; Figure 5).
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Acute effects of hot water extract of four most potent plants (A and C) A. latifolia, A. marmelos, T. foenum graecum,
M. indica and (B and D) DPP-IV inhibitors: sitagliptin and vidagliptin on (A and B) glucose tolerance and (C and D) plasma
insulin in high-fat fed rats expressed as line graphs and area under the curve
Blood glucose and plasma insulin were measured prior to and after oral administration of glucose alone (18 mmol/kg body weight,
control) or in combination with plant extract (250 mg/5 ml/kg body weight,), Sitagliptin or Vidagliptin (both at 10 μmol/5 ml/kg, body
weight). Values are mean +− SEM with n=6, *P<0.05, **P<0.01 and ***P<0.001, compared with lean rats and P<0.05, P<0.01
and P<0.001 compared with high-fat fed controls.
Discussion
DPP-IV inhibitors are used in the treatment of T2DM based on their ability to extend postprandial levels of circulating
plasma GLP-1 and GIP, thereby improving insulin secretion and helping to maintain good blood glucose control. Since
their introduction to the clinic [15], this drug class has proven to be effective and highly popular. Weight reduction
and glycaemic control are inferior to the related family of GLP-1 mimetics but DPP-IV inhibitors have the advantage
of being orally active, thereby avoiding the need for daily injections and increasing patient compliance. In certain
developing countries, the limited availability and cost of these and other modern medicines, such as metformin,
sulphonylureas, thiazolidenediones, SGLT2 inhibitors and insulin formulations, have resulted in increasing attention
being paid to traditional plant medicines with reputed anti-diabetic activity for treatment of T2DM [3,8,10,16–18].
A considerable number of plants have been used traditionally for the treatment for diabetes and its complications
but only a limited number have been subjected to scientific scrutiny and fewer still scrutinized for the mechanisms
responsible for their anti-diabetic effects [9,16,19]. In the present study, we have examined 22 medicinal plants with
proven glucose-lowering ability (Table 2) to assess whether part of their mode of action relates to an ability to inhibit
DPP-IV. Hot water extracts of every plant studied exhibited some degree of DPP-IV inhibition in vitro ranging from
9 to 96%, but the most substantial effects were observed (in descending order) with A. latifolia (bark), A. marmelos
(leaves), M. indica (seeds), T. foenum-graecum (seeds), C. cochinchinensis (bark), and A indica (seeds). These
plants inhibited DPP-IV by 27–96% with IC25 values of 446–4720 μg/ml. Although considerably less effective than
pure preparations of sitagliptin and vildagliptin, these observations suggest that a component of the anti-diabetic
actions of these plants may be due to inhibition of DPP-IV. This adds to the results of previous studies which have
8 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Acute effects of hot water extract of four most potent plants (A) A. latifolia, (B) A. marmelos, (C) T. foenum graecum
and (D) M. indica on DPP-IV activity in high-fat fed rats expressed as line graphs and area under the curve
Plasma DPP-IV activity was measured prior to and after oral administration of glucose alone (18 mmol/kg body weight, control) or
in combination with plant extract (250 mg/5 ml/kg body weight), Sitagliptin or Vidagliptin (each at 10 μmol/5 ml/kg body weight).
DPP-IV activity was determined by Gly-Pro-AMC (200 μM) cleavage. Values are mean +− SEM with n=6, *P<0.05, **P<0.01 and
***P<0.001, compared with lean rats and P<0.05, P<0.01 and P<0.001 compared with high-fat fed controls.
highlighted gastrointestinal effects of anti-diabetic plants and their ability to enhance insulin secretion and/or action
[20–23].
Based on these in vitro results, the four most active plants were selected from the 22 initially screened for in vivo
evaluation of effects on oral glucose tolerance, insulin secretion and plasma DPP-IV activity using high-fat fed rats.
This included A. latifolia, A. marmelos, T. foenum-graecum and M. indica. The first two were particularly effective
in inhibiting DPP-IV in vitro with up to 44-96% inhibition and IC50 values of 754-790 μg/ml. This compares with
almost total inhibition of DPP-IV by sitagliptin and vildagliptin with IC25 and IC50 values of 2.04 × 10−3 to 2.43 ×
10−3 μg/ml and 2.04 × 10−2 to 1.70×10−2 μg/ml, respectively. As expected, administration of either sitagliptin or
vildagliptin orally to high fat fed obese-diabetic rats, together with glucose, induced a remarkable improvement in
glucose tolerance and glucose-stimulated insulin secretion. This was associated with a 70–72% decrease in plasma
DPP-IV activity known to result in strong augmentation of the stimulatory insulin-releasing effects of the incretin
hormones GLP-1 and GIP. Consistent with this, circulating concentrations of active GLP-1 (7-36) were increased
by 81–89% at 60 min following administration of these DPP-IV inhibitors. Extracts of A. latifolia, A. marmelos,
T. foenum-graecum and M. indica also significantly inhibited DPP-IV enzyme activity and increased active GLP-1
(7-36) but by lesser extents of 12–18% and 32–45%, respectively. Interestingly, the glucose lowering actions of the four
plant extracts were very similar to the DPP-IV inhibitors despite a smaller plasma insulin response. This indicates
that other factors such as a delayed glucose absorption make a major contribution to the acute anti-hyperglycaemic
activity of these plants in vivo [9,23]. Further long-term studies are required to determine how their effects compare
with other plant-derived substances that exhibit anti-diabetic properties, such as metformin.
These results suggest that many plants used traditionally to treat diabetes have orally available constituents that in-
hibit DPP-IV, thereby contributing to their spectrum of actions which in the case of some might be significant [24,25].
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. Acute effects of hot water extract of four most potent plants: A. latifolia, A. marmelos, T. foenum graecum and M.
indica on plasma active GLP-1 (7-36) in high-fat fed rats
Plasma active GLP-1 (7-36) concentrations was measured at 60 min after oral administration of glucose alone (18 mmol/kg body
weight, control) or in combination with plant extract (250 mg/5 ml/kg body weight), Sitagliptin or Vidagliptin (both at 10 μmol/5
ml/kg, body weight). Values are mean +− SEM with n=6, *P<0.05, **P<0.01 compared with lean rats and P<0.05, P<0.01 and
P<0.001 compared with high-fat fed controls.
Indeed, additional in vitro and in vivo studies on individual plant extracts have reported that other plant species in-
hibit DPP-IV activity [26,27]. These observations suggest that these plant extracts exert part of their insulinotropic
effects via inhibition of DPP-IV with resultant preservation of active forms of GLP-1 (7-36) and GIP (1-42) released
from intestinal enteroendocrine cells by feeding. Overall, our results together with these previous studies indicate that
net effects on insulin secreting cells reflect combination of direct actions of glucose and other nutrients compounded
by potentiating effects of incretin hormones that are favored by the concurrent inhibition of DPP-IV. Further ex-
tensive studies will be required to measure active and total forms of GLP-1 and GIP following administration of the
plants studied but the few reports in the literature suggest that some plants with reputed anti-diabetic activity increase
circulating GLP-1 [28]. The extent to which this may reflect enhanced secretion as opposed to decreased degradation
by DPP-IV is unknown.
Although the present study describes DPP-IV lowering activity of many medicinal plants with anti-diabetic ac-
tions, few precise details are known about the nature of the phytochemicals that are absorbed and subsequently inhibit
DPP-IV. All 22 plants examined inhibited DPP-IV activity in vitro to some extent suggesting that such chemicals are
commonly encountered in the plant kingdom. Studies to date suggest that these include alkaloids, glycosides, ter-
penoids, phenolic, flavonoids as well as protein hydrolysates and peptides [27,2]. These may act at the molecular level
by binding to the active site of the enzyme, thereby inhibiting interactions with natural substrates. Small peptides
may also serve as competitive substrates as is the case with diprotin-A. Indeed, we demonstrated DPP-IV inhibitory
action for caffeine, catechin, epicatechin, gallic acid, isoquercitrin, quercetin and rutin which may realistically con-
tribute to the observed effects as they have been reported to be present in plants at levels of up to 2–30% by weight,
not accounting for losses during our extraction procedure [29]. Rutin is the most abundant of these phytochemicals
and was also shown to be the most effective inhibitor of DPP-IV, with an action broadly similar to that observed
with the established anti-diabetic drug, nateglinide. The active plant constituents might, like this meglitinide, serve
as effective prandial blood glucose regulators stemming partly from their ability to preserve active forms of GLP-1
and GIP released by feeding [6].
10 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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(%) IC25 (μg/ml) Estimated IC50 (μg/ml)
Sitagliptin (Inhibitor) 4.07 × 10−4 99 +− 2‡ 2.04 × 10−3 2.04 × 10−2
Vidagliptin (Inhibitor) 6.07 × 10−4 99 +− 3‡ 2.43 × 10−3 1.70 × 10−2
Diprotin A (Inhibitor) 95 +− 3‡ 1.02 × 10−3 2.39 × 10−3
Anogeissus latifolia 200 96 +− 1‡ 590 754
Aegle marmelos (L.) Corrêa 200 44 +− 7† 446 790
Mangifera indica L. 200 38 +− 4‡ 2000 —
Cudrania cochinchinensis (Lour.) 1000 31 +− 1‡ 4,050 —
Trigonella foenum-graecum L. 200 28 +− 2‡ 4,700 —
Azadirachta indica 1000 27 +− 2‡ 4,720 —
Tamarindus indica 200 23 +− 2‡ — —
Terminalia arjuna (Roxb. ex DC.) 200 22 +− 1‡ — —
Acacia catechu (L.f.) Willd. 5000 22 +− 7* — —
Withania coagulans (Stocks) 1000 17 +− 3† — —
Sesamum indicum (White) 40 19 +− 5* — —
Albizia lebbeck (L.) Benth. 5000 19 +− 4† — —
Cassia fistula L. 5000 19 +− 6* — —
Santalum album L. 40 17 +− 5* — —
Eugenia jambolana Lam. 40 14 +− 5* — —
Selaginella bryopteris (L.) 1000 13 +− 4* — —
Momordica charantia L. 1000 13 +− 2† — —
Swertia chirayita (Roxb.) 5000 12 +− 1† — —
Glycyrrhiza glabra L. 200 12 +− 2* — —
Bunium persicum (Boiss.) 200 11 +− 3* — —
Dalbergia sissoo DC. 5000 10 +− 2* — —
Linum usitatissimum L. 40 9 +− 1* — —
DPP-IV inhibitory activity of hot water extracts of various plants when incubated with Gly-Pro-AMC (200 μM) plus DPP4 (8 mU/ml−1) for 30 min at
37◦C. Sitagliptin, Vidagliptin and Diprotin A were used as established inhibitors. Values are mean +− SEM with n=4. *P<0.05, †P<0.01 and ‡P<0.001
compared with control group Gly-Pro-AMC (200 μM) + DPP4 (8 mU/ml−1) alone. The calculated IC50 (μg/ml) was an estimate.
In the light of the DPP-IV inhibitory actions of the 22 plants tested plus the selected phytochemicals, it is notable
that flavonoids and their metabolites have been reported to exhibit anti-diabetic activities. An inverse relationship has
been suggested also between flavonoid intake and T2DM risk [30]. Phytochemicals other than those tested, such as
anthocyanin, aspalathin, chrysin, eriodictyol, hispidulin, kaempferol, lepidoside, mangiferin, naringenin, naringin,
procyanidin, rhamnoside, terpenoids, vitexin and Lens culinaris extracts have been shown also to exhibit DPP-IV
inhibitory activity [27,31]. In addition, a number of other plants (such as A. catechu, M. indica and A. marmelos)
have been reported to contain potential phenolic compounds that exert antioxidant effects and DPP-IV inhibitory
activity [32].
Conclusions
In conclusion, these findings indicate that a substantial proportion of plants used traditionally for the treatment of
diabetes exhibit DPP-IV inhibitory activity which may contribute to their multiple glucose lowering actions. Such
medicinal plants could provide an accessible therapy for diabetes particularly in populations without easy access to
the recognized drugs. More work is required for isolation, identification and characterization of agents responsible
for inhibition of DPP-IV but there is a good chance that multiple phytochemicals are involved in mediating such
effects [33].
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